Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.

OBJECTIVE Anti-tumor necrosis factor alpha (anti-TNF) therapy is a mainstay of treatment in rheumatoid arthritis (RA). The aim of the present study was to test established RA genetic risk factors to determine whether the same alleles also influence the response to anti-TNF therapy. METHODS A total of 1,283 RA patients receiving etanercept, infliximab, or adalimumab therapy were studied from among an international collaborative consortium of 9 different RA cohorts. The primary end point compared RA patients with a good treatment response according to the European League Against Rheumatism (EULAR) response criteria (n = 505) with RA patients considered to be nonresponders (n = 316). The secondary end point was the change from baseline in the level of disease activity according to the Disease Activity Score in 28 joints (triangle upDAS28). Clinical factors such as age, sex, and concomitant medications were tested as possible correlates of treatment response. Thirty-one single-nucleotide polymorphisms (SNPs) associated with the risk of RA were genotyped and tested for any association with treatment response, using univariate and multivariate logistic regression models. RESULTS Of the 31 RA-associated risk alleles, a SNP at the PTPRC (also known as CD45) gene locus (rs10919563) was associated with the primary end point, a EULAR good response versus no response (odds ratio [OR] 0.55, P = 0.0001 in the multivariate model). Similar results were obtained using the secondary end point, the triangle upDAS28 (P = 0.0002). There was suggestive evidence of a stronger association in autoantibody-positive patients with RA (OR 0.55, 95% confidence interval [95% CI] 0.39-0.76) as compared with autoantibody-negative patients (OR 0.90, 95% CI 0.41-1.99). CONCLUSION Statistically significant associations were observed between the response to anti-TNF therapy and an RA risk allele at the PTPRC gene locus. Additional studies will be required to replicate this finding in additional patient collections.

[1]  P. Donnelly,et al.  A new multipoint method for genome-wide association studies by imputation of genotypes , 2007, Nature Genetics.

[2]  M. Daly,et al.  Genetic variants at CD28, PRDM1, and CD2/CD58 are associated with rheumatoid arthritis risk , 2009, Nature Genetics.

[3]  H. Tiwari,et al.  The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. , 2004, Arthritis and rheumatism.

[4]  F. Brennan,et al.  CD45-induced Tumor Necrosis Factor α Production in Monocytes Is Phosphatidylinositol 3-Kinase-dependent and Nuclear Factor-κB-independent* , 1999, The Journal of Biological Chemistry.

[5]  Pardis C Sabeti,et al.  A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC , 2006, Nature Genetics.

[6]  A. Silman,et al.  Predictors of Response to Anti-tnf-therapy among Patients with Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register , 2022 .

[7]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.

[8]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[9]  Yusuke Nakamura,et al.  Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis , 2003, Nature Genetics.

[10]  Josef M. Penninger,et al.  CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling , 2001, Nature.

[11]  Eric S. Lander,et al.  The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes , 2000, Nature Genetics.

[12]  Steven J. Schrodi,et al.  A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. , 2004, American journal of human genetics.

[13]  B. Dijkmans,et al.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.

[14]  Annette Lee,et al.  Several Regions in the Major Histocompatibility Complex Confer Risk for Anti-CCP-Antibody Positive Rheumatoid Arthritis, Independent of the DRB1 Locus , 2008, Molecular medicine.

[15]  A. Barton,et al.  Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients , 2009, Pharmacogenetics and genomics.

[16]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[17]  Ann Morgan,et al.  Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility , 2008, Human molecular genetics.

[18]  K. Mossman.  The Wellcome Trust Case Control Consortium, U.K. , 2008 .

[19]  Xiayi Ke,et al.  Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13 , 2008, Nature Genetics.

[20]  J. Avorn,et al.  The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28 , 2006, Arthritis research & therapy.

[21]  A. Barton,et al.  Recent advances in the genetics of RA susceptibility. , 2007, Rheumatology.

[22]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[23]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[24]  P. Gregersen,et al.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[25]  Lars Alfredsson,et al.  A Candidate Gene Approach Identifies the TRAF1/C5 Region as a Risk Factor for Rheumatoid Arthritis , 2007, PLoS Medicine.

[26]  L. Klareskog,et al.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.

[27]  Jing Cui,et al.  Common variants at CD40 and other loci confer risk of rheumatoid arthritis , 2008, Nature Genetics.

[28]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[29]  B. Dijkmans,et al.  The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium , 2007, Annals of the rheumatic diseases.

[30]  Wentian Li,et al.  Genome-Wide Association Scan Identifies Candidate Polymorphisms Associated with Differential Response to Anti-TNF Treatment in Rheumatoid Arthritis , 2008, Molecular medicine.

[31]  Elizabeth W Karlson,et al.  Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. , 2005, American journal of human genetics.

[32]  R. Plenge,et al.  Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions , 2008, Current opinion in rheumatology.

[33]  B. Franke,et al.  Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. , 2007, American journal of human genetics.

[34]  L. Padyukov,et al.  Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[35]  Anbupalam Thalamuthu,et al.  TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study. , 2007, The New England journal of medicine.

[36]  M. Liang,et al.  Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. , 2006, Arthritis and rheumatism.

[37]  D. M. van der Heijde,et al.  The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28 , 2006, Arthritis research & therapy.

[38]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[39]  R. Plenge,et al.  Recent progress in rheumatoid arthritis genetics: one step towards improved patient care , 2009, Current opinion in rheumatology.

[40]  P. Gregersen,et al.  The PRL -1149 G/T polymorphism and rheumatoid arthritis susceptibility. , 2009, Arthritis and rheumatism.

[41]  L. Klareskog,et al.  Swedish registers to examine drug safety and clinical issues in RA , 2006, Annals of the rheumatic diseases.

[42]  M. Hermiston,et al.  CD45: a critical regulator of signaling thresholds in immune cells. , 2003, Annual review of immunology.

[43]  Richard W Grant,et al.  Physician ability to assess rheumatoid arthritis disease activity using an electronic medical record-based disease activity calculator. , 2009, Arthritis and rheumatism.

[44]  A. Barton,et al.  Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis , 2008 .

[45]  S. Gabriel,et al.  Two independent alleles at 6q23 associated with risk of rheumatoid arthritis , 2007, Nature Genetics.

[46]  D. Strachan,et al.  Rheumatoid arthritis association at 6q23 , 2007, Nature Genetics.

[47]  Sekar Kathiresan,et al.  Defining the spectrum of alleles that contribute to blood lipid concentrations in humans , 2008, Current opinion in lipidology.

[48]  M. Prevoo,et al.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. , 1996, Arthritis and rheumatism.

[49]  C. Wijbrandts,et al.  Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss , 2008, Annals of the rheumatic diseases.

[50]  M. Daly,et al.  Guilt by association , 2000, Nature Genetics.

[51]  Y. Kamatani,et al.  Functional SNPs in CD244 increase the risk of rheumatoid arthritis in a Japanese population , 2008, Nature Genetics.

[52]  Larry W. Moreland,et al.  REL, a member of the NF-κB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis , 2009, Nature Genetics.